Sel’skokhozyaistvennaya Biologiya [Agricultural Biology], 2018, Vol. 53, ¹ 4, p. 851-859.
(how to cite this article)

doi: 10.15389/agrobiology.2018.4.851eng

UDC 636.4:619:615.375

 

PORCINE BIFERON-C APPLIED TOGETHER WITH MEDICINAL
PROPHYLAXIS IN COMMERCIAL PIG BREEDING PROVIDES
IMMUNOSTIMULATION OF SOWS AND AN INCREASED VIABILITY
OF THEIR PIGLETS

S.V. Shabunin, A.G. Shakhov, G.A. Vostroilova, L.V. Cheskidova,
P.A. Parshin, T.I. Ermakova, N.A. Grigoryeva

All-Russian Research Veterinary Institute of Pathology, Pharmacology and Therapy RAAS, Federal Agency of Scientific Organizations, 114-b, ul. Lomonosova, Voronezh, 394087 Russia, e-mail gvostroilova@mail.ru (✉ corresponding author), vnivipat@mail.ru, A.G.Shakhov@mail.ru, lvcheskidova@yandex.ru, doktor57@mail.ru, ermakova53@list.ru, kettbery@mail.ru

ORCID:
Shabunin S.V. orcid.org/0000-0002-2689-6998
Parshin P.A. orcid.org/ 0000-0002-8790-0540
Shakhov A.G. orcid.org/0000-0002-6177-8858
Ermakova T.I. orcid.org/ 0000-0003-1069-1223
Vostroilova G.A. orcid.org/0000-0002-2960-038X
Grigoryeva N.A. orcid.org/0000-0002-7593-1198
Cheskidova L.V. orcid.org/0000-0003-0196-1754
The authors declare no conflict of interests

Received February 8, 2018

 

Immunodeficiency of pigs resulting from the effect of various infectious and invasive pathogens, mycotoxins, heavy metals, wide usage of chemotherapeutic agents and other xenobiotics, nutritional deficiencies, deficiency of some vitamins and microelements, stresses of various etiology is one of the main causes of high morbidity in breeder herds and the offspring. In this paper, the immune status of sows and safety of suckling piglets under the effect of recombinant alpha- and gamma-interferons, the main active substances of Biferon-C preparation (the Republic of Belarus), applied in combination with conventional measures for prophylaxis with antibiotics and chemoprophylaxis are studied for the first time. It is found that the treatment of sows improves their immune status with a 2-fold increase in safety of their piglets while the offspring of untreated sows shows only a 4 % increase in viability after injections of Biferon-C. For the experiment, two groups of 10 farrow sows each were formed (Zolotaya Niva, Znamenskii Region, Tambov Province, 2017). The animals of basic variant (group I) were treated after farrowing according to the scheme accepted in the farm: during the first 24 hours after farrowing and on day 3 and day 5, one time a day, sows were intramascularly injected with Metramag and treated intrauterinely with Iodopen. Sows of test group II were additionally injected intramuscularly with Biferon-C (10 ml per sow) 24 hours before farrowing and 2 days post farrowing. Newborn piglets of group I born from mother sows not treated with Biferon-C (basic variant, n = 332) were treated according to the scheme accepted in the farm, and the animals of test group II (n = 333) additionally received two intramascular injections of Biferon-C (0.1 ml/kg of body weight) at 24-hour intervals. Experimental sows and piglets were clinically observed till weaning (24-26 day), considering the percent of morbidity, mortality and growth dynamics of piglets. Blood samples were tested for morphological and immunological indices before the application of the preparations and at the end of the experiment. The basic level of immune indices showed that immune status of sows of all the groups practically did not differ and corresponded to their physiological state. Receiving recombinant proteins by sows led to a significant increase in relevant and absolute blood levels of monocytes, lymphocytes, T- and B-lymphocytes, complementary and lysozyme blood serum activity, phagocytosis. Higher immune status of sows promoted the prophylaxis of their postpartum pathologies and a 2-fold increase in viability of their litters. The injectionû of Biferon-C to piglets led to the decrease in intestinal infection frequency, increasing the safety of the herd.

Keywords: Biferon-C, recombinant proteins, immune status, sows, piglets, postpartum pathology, intestinal infections.

 

Full article (Rus)

Full article (Eng)

 

REFERENCES

  1. Cho J.G., Dee S.A., Dee J., Guedes A., Trincado C., Fano E., Faaberd K., Collins J.E., Joo H.S. Evaluation of the effect of animals age, concurrent bacterial infection, and pathogenicity of porcine reproductive and respiratory syndrome virus concentration in pigs. Vet. Res., 2006, 67(3): 489-493 CrossRef
  2. Gerjets I., Traulsen I., Reiners K., Kemper N. Comparison of virulence gene profiles of isolates from sows with Coliform mastitis and healthy sows. Vet. Microbiol., 2011, 152(3-4): 361-367 CrossRef
  3. Donnik I.M., Bezborodova N.A. Agrarnyi vestnik Urala, 2009, 8: 84-89 (in Russ.).
  4. Iheshiulor O.O.M., Esonu B.O., Chuwuka O.K., Omede A.A., Okoli I.C., Ogbuewu I.P. Effects of mycotoxins in animal nutrition: A review. Asian J. Anim. Sci., 2011, 5(1): 19-33 CrossRef
  5. Mirzoev E.B., Kobyalko V.O., Aleksakhin R.M. Scientific approaches to ensuring of stable development of livestock sector in ecologically unfavorable regions. Sel’skokhozyaistvennaya Biologiya [Agricultural Biology], 2011, 6: 11-18(in Russ.).
  6. Popov V.S., Samburov N.V., Zorikova A.A. Vestnik Kurskoi gosudarstvennoi sel'skokhozyaistvennoi akademii, 2016, 4: 63-67 (in Russ.).
  7. Peisak Z. Zashchita zdorov'ya svinei [Health protection in pigs]. Brest, 2012 (in Russ.).
  8. Kovalenko A.B., Mironova O.A. Zootekhniya, 2009, 3: 29-30 (in Russ.).
  9. Kotsarev V.N. Veterinariya, 2005, 3: 39-43 (in Russ.).
  10. Jenny B., Vidondo B., Pendl W., Kümmerlen D., Sidler X. Erhebung von Risikofaktoren für Mastitis-Metritis-Agalaktie in Schweine-betrieben in der Schweiz. Schweizer Archiv für Tierheilkunde, 2015, 157(12): 689-696 CrossRef
  11. Geetha T., Tensingh Gnanaraj P. A case report of mastitis-metritis-agalactia syndrome (MMA) in a sow. Indian Vet. J., 2017, 94(12): 56-57.
  12. Makarov V.V. Faktornye bolezni. Rossiiskii veterinarnyi zhurnal, 2017, 4: 22-27 (in Russ.).
  13. Shakhov A.G., Anufriev A., Anufriev P.A. Zhivotnovodstvo Rossii, 2005, spets. vyp. po svinovodstvu: 24-27 (in Russ.).
  14. Krasochko P.A. Immunokorrektsiya v klinicheskoi veterinarnoi meditsine: Monografiya [Immunocorrection in clinical veterinary medicine: monograph]. Minsk, 2008 (in Russ.).
  15. Kovalenko V.L., Shved V.V. Veterinarna b³otekhnolog³ya, 2013, 23(23): 184-186.
  16. Biron C.A. Interferons a and β as immune regulators — a new look. Immunity, 2001, 14: 662-664 CrossRef
  17. Vilcek J. Fifty years of interferon research: aiming at a moving target. Immunity, 2006, 25(3): 343-348 CrossRef
  18. Beekhuizen H., van de Gevel J.S. Gamma interferon confers resistance to infection with Staphylococcus aureus in human vascular endothelial cells by cooperative proinflammatory and enhanced intrinsic antibacterial activities. Infection and Immunity, 2007, 75(12): 5615-5626 CrossRef
  19. Eshleman E.M., Lenz L.L. Type I interferons in bacterial infections: taming of myeloid cells and possible implications for autoimmunity. Front Immunol., 2014, 5: 431 CrossRef
  20. Johnson H.M. Gamma interferon: from antimicrobial activity to immune regulation. Front. Immunol., 2015, 5: 667 CrossRef
  21. Boxx G.M., Cheng G. The roles of type I interferon in bacterial infection. Cell Host & Microbe, 2016, 19(6): 760-769 CrossRef
  22. Baron S., Weigent D., Stanton G.J., Peterson J. The protective role of endogenous interferon in viral, bacterial and protozoal infection. Antiviral Res., 1985, 5(Suppl. 1): 173-183 CrossRef
  23. Prokulevich V.A., Potapovich M.I. Vestnik BGU, Ser. 2, 2011, 3: 51-55 (in Russ.).
  24. Vasil'ev A.N., Deryabin P.G., Galegov G.A. Antibiotiki i khimioterapiya, 2011, 56 (9-10): 27-32 (in Russ.).
  25. Razaghi A., Owens L., Heimann K. Review of the recombinant human interferon gamma as an immunotherapeutic: impacts of production platforms and glycosylation. J. Biotechnol., 2016, 240: 48-60 CrossRef
  26. Parkhomenko S.A., Zeinalov O.A. Rossiiskii veterinarnyi zhurnal, 2017, 5: 26-29 (in Russ.).
  27. Kozlova O.A., Medvedev G.F., Potapovich M.I., Prokulevich V.A. V sbornike: Aktual'nye problemy intensivnogo razvitiya zhivotnovodstva [In: Challenges of intensive livestock development. Iss. 21, Part 2]. Gorki, 2018, vyp. 21, ch. 2: 3-10 (in Russ.).
  28. Pakhmutov I.A., Ul'yanova I.A. Veterinariya, 1984, 3: 68-69 (in Russ.).
  29. Entsiklopediya immunologii. Tom 1 /Pod redaktsiei A.M. Zemskova, V.M. Zemskova, V.A. Chereshneva [Encyclopedia of immunology. V. 1. A.M. Zemskov, V.M. Zemskov, V.A. Chereshnev (eds.)]. Moscow, 2013 (in Russ.).
  30. Tarasova G.N., Fedotova E.N., Chumakova E.A., Il'yashenko M.G. Prakticheskaya meditsina. Pediatriya, 2012, 7(62): 170-173 (Russ.).
  31. Rönnblom L. The importance of the type I interferon system in autoimmunity. Clin. Exp. Rheumatol., 2016, 34(4 Supple. 98): 21-24.
  32. González-Navajas J.M., Lee J., David M., Raz E. Immunomodulatory functions of type I interferons. Nature Reviews Immunology, 2012, 12: 125-135 CrossRef
  33. Boasso A. Type I interferon at the interface of antiviral immunity and immune regulation: the curious case of HIV-1. Scientifica, 2013, 2013: Article ID 580968 CrossRef
  34. Inada T., Kubo K., Shingu K. Promotion of interferon-gamma production by natural killer cells via suppression of murine peritoneal macrophage prostaglandin E2 production using intravenous anesthetic propofol. International Immunopharmacology, 2010, 10(10): 1200-1208 CrossRef
  35. Sysoeva G.M., Danilenko E.D., Medvedeva T.B., Korovina O.S., Levagina G.M, Masycheva V.I. Vestnik Ural'skoi meditsinskoi akademicheskoi nauki, 2011, 2/2(35): 68-69 (in Russ.). 
  36. Su X., Yu Y., Zhong Y., Giannopoulou E.G., Hu X., Liu H., Cross J.R., Rätsch G., Rice C.M., Ivashkiv L.B. Interferon-γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation. Nature Immunology, 2015, 16: 838-849 CrossRef
  37. Avau A., Matthys P. Therapeutic potential of interferon-γ and its antagonists in autoinflammation: lessons from murine models of systemic juvenile idiopathic arthritis and macrophage activation syndrome. Pharmaceuticals, 2015, 8(4): 793-815 CrossRef
Korovina O.S., Gamalei S.G., Batenev A.V, Korneev D.V., Medikova L.D., Levagina G.M., Danilenko E.D., Bagryantseva M.P. Vestnik Ural'skoi meditsinskoi akademicheskoi nauki, 2011, 2/1(29): 40 (in Russ.). 

 

back